Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients

Kronenberg, Florian; Lingenhel, Arno; Neyer, Ulrich; Lhotta, Karl; König, Paul; Auinger, Martin; Wiesholzer, Martin; Andersson, Heléne; Dieplinger, Hans

doi:10.1046/j.1523-1755.63.s84.23.x

Cited by 79 publications

(78 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27 Recent studies indicated that PD patients have higher serum triglyceride, Lp (a), small dense LDL-cholesterol levels and reduced HDL-cholesterol concentrations when compared to HD patients. 28,29 This heightened risk might be attributed to many factors including lose of proteins via peritoneal membrane, increased absorption of glucose from dialysate and increased serum levels of insulin in this population. 30 In accordance to these study results, usage of icodextrincontaining dialysis solutions was found to be superior to glucose-containing dialysis solutions in terms of lowering serum triglycerides and small dense LDL concentrations.…”

Section: Discussionmentioning

confidence: 99%

The relationship between atherogenic index of plasma and epicardial adipose tissue in hemodialysis and peritoneal dialysis patients

Erdur¹,

Tonbul²,

Özbiner

et al. 2013

Renal Failure

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The relationship between atherogenic index of plasma and epicardial adipose tissue in hemodialysis and peritoneal dialysis patients

Erdur¹,

Tonbul²,

Özbiner

et al. 2013

Renal Failure

View full text Add to dashboard Cite

“…22,23 We also found that in the PD group, patients have higher cholesterol and Apo-B levels than in HD group, as reported previously. 7,24,25 A possible explanation for this abnormality is the exposure of patients to glucose in the dialysate and insulin resistance that activates the delivery of free fatty acids (FFAs) to the liver and subsequently the oxidation or esterification of FFAs to cytosolic triglycerides or VLDL. 26,27 The increase of Apo-B concentration in PD patients may possibly enhance the production of Apo-B containing, triglyceride-rich atherogenic particles.…”

Section: Discussionmentioning

confidence: 99%

Lipid Abnormalities and Oxidized LDL in Chronic Kidney Disease Patients on Hemodialysis and Peritoneal Dialysis

et al. 2011

View full text Add to dashboard Cite

Dyslipoproteinemia and oxidative modification of low-density lipoprotein (oxLDL) contribute to the development of oxidative stress and atherosclerosis in chronic kidney disease (CKD). On the contrary, high-density lipoprotein cholesterol (HDL-C), especially HDL3-C subtype, has protective effect against oxidative damage. There is limited evidence referring HDL-C subclass levels in patients on dialysis. This study was designed to compare lipid abnormalities and oxLDL levels in hemodialysis (HD) and peritoneal dialysis (PD) patients. Serum lipids, HDL subclasses, and oxLDL were measured in 55 patients with CKD-stage 5 (31 patients on HD and 24 patients on PD) and in 21 normal controls (NC). The results showed that in dialysis patients, triglycerides were higher than in controls (p < 0.0001) and HDL-C was significantly lower (p < 0.0001). The HDL2-C subclass concentration did not differ significantly between patients and controls, while HDL3-C was lower in patients (11 ± 0.5 mg/dL) than in NC (23 ± 1, p < 0.0001). oxLDL levels were markedly increased in patients (1.92 ± 0.29 mg/L) compared to NC (0.22 ± 0.05, p < 0.0001). Patients on PD had higher levels of cholesterol (p < 0.001) and apolipoprotein B (p < 0.05) than patients on HD. However, HDL-C, HDL-C subclasses, and oxLDL concentrations did not differ significantly between PD and HD patients. It is concluded that patients with CKD have a nearly 10-fold elevation of oxLDL compared with NC. Patients on PD have differences in the lipid profile compared with patients on HD; however, both modalities seem to possess similar potential to atherosclerosis development.

show abstract

“…Patients on maintenance haemodialysis treatment have a higher prevalence of elevated blood cholesterol when compared with the general population (Ma et al 1992;Kronenberg et al 2003). The management of hypercholesterolaemia is one of the important therapeutic goals for patients on haemodialysis (Levey et al 1998;Sarnak, 2003), and dietary therapy is an integral component of the treatment of hypercholesterolaemia.…”

mentioning

confidence: 99%

Effect of soya protein on serum lipid profile and lipoprotein concentrations in patients undergoing hypercholesterolaemic haemodialysis

Chen

Yang

et al. 2006

Br J Nutr

View full text Add to dashboard Cite

Clinical trials have shown that soya protein reduces the concentrations of some atherogenic lipids in subjects with normal renal function. The present study examined the effects of soya protein on serum lipid concentrations and lipoprotein metabolism in patients on hypercholesterolaemic haemodialysis. Twenty-six hypercholesterolaemic (total cholesterol $ 6·21 mmol/l) patients on haemodialysis were studied in a randomized, double-blind, placebo-controlled clinical trial. After a 4-week run-in phase, the subjects were randomly assigned to two groups. Isolated soya protein or milk protein 30 g was consumed daily as a beverage at breakfast or post-dialysis for 12 weeks. Soya protein substitution resulted in significant reductions in total cholesterol (17·2 (SD 8·9 )%), LDL-cholesterol (15·3 (SD 12·5 )%), apo B (14·6 (SD 12·1 )%) and insulin (23·8 (SD 18·7) %) concentrations. There were no significant changes in HDL-cholesterol or apo A-I. These results indicate that replacing part of the daily protein intake with soya protein has a beneficial effect on atherogenic lipids and favourably affects lipoprotein metabolism in hypercholesterolaemic patients undergoing haemodialysis.

show abstract

Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients

Abstract: Dyslipidemic risk factors are highly prevalent in dialysis patients, and the concomitant occurrence of several risk factors in a given patient is more often observed in CAPD than HD patients.

Cited by 79 publications

References 15 publications

The relationship between atherogenic index of plasma and epicardial adipose tissue in hemodialysis and peritoneal dialysis patients

The relationship between atherogenic index of plasma and epicardial adipose tissue in hemodialysis and peritoneal dialysis patients

Lipid Abnormalities and Oxidized LDL in Chronic Kidney Disease Patients on Hemodialysis and Peritoneal Dialysis

Effect of soya protein on serum lipid profile and lipoprotein concentrations in patients undergoing hypercholesterolaemic haemodialysis

Contact Info

Product

Resources

About